Haradhvala, Nicholas J. http://orcid.org/0000-0003-1113-3135
Leick, Mark B.
Maurer, Katie http://orcid.org/0000-0002-4160-181X
Gohil, Satyen H.
Larson, Rebecca C.
Yao, Ning
Gallagher, Kathleen M. E.
Katsis, Katelin
Frigault, Matthew J. http://orcid.org/0000-0002-6774-5694
Southard, Jackson
Li, Shuqiang
Kann, Michael C. http://orcid.org/0000-0002-5917-0296
Silva, Harrison
Jan, Max
Rhrissorrakrai, Kahn
Utro, Filippo http://orcid.org/0000-0003-3226-7642
Levovitz, Chaya http://orcid.org/0000-0002-9251-2294
Jacobs, Raquel A.
Slowik, Kara
Danysh, Brian P. http://orcid.org/0000-0001-6839-6337
Livak, Kenneth J. http://orcid.org/0000-0001-9105-5856
Parida, Laxmi http://orcid.org/0000-0002-7872-5074
Ferry, Judith
Jacobson, Caron
Wu, Catherine J. http://orcid.org/0000-0002-3348-5054
Getz, Gad http://orcid.org/0000-0002-0936-0753
Maus, Marcela V. http://orcid.org/0000-0002-7578-0393
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA252940, R50CA251956, R01CA252940)
Landry Cancer Biology Consortium, IBM Research
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (T32 AI007529)
Article History
Received: 24 March 2022
Accepted: 19 July 2022
First Online: 12 September 2022
Competing interests
: N.J.H. is a consultant for MorphoSys. C.J.W. holds equity in BioNTech Inc. and receives research funding from Pharmacyclics. S.H.G. holds patents related to adoptive cell therapies, held by University College London and Novalgen Limited. S.H.G. provides consultancy to Novalgen Ltd. G.G. receives research funds from IBM and Pharmacyclics, and is an inventor on patent applications related to MSMuTect, MSMutSig, MSIDetect, POLYSOLVER and SignatureAnalyzer-GPU. G.G. is a founder, consultant and holds privately held equity in Scorpion Therapeutics. M.V.M., M.B.L. and R.C.L. are inventors on patents related to adoptive cell therapies, held by MGH. M.V.M. is also an inventor on patents related to CAR-T cell therapies held by the University of Pennsylvania (some licensed to Novartis). M.V.M. is on the Board of Directors of 2SeventyBio, and holds equity in TCR2, Century Therapeutics, Oncternal and Neximmune, and has served as a consultant for multiple companies involved in cell therapies. The other authors declare no competing interests.